ライフサイエンスコーパス: heart beat

1 induced by right ventricular pacing (25% of heart beats).

2 red with vitamin C (+10.0 +/- 6.9 bursts/100 heart beats).

3 ly and rejection was defined by cessation of heart beat.

4 sponsible for originating and regulating the heart beat.

5 are evident even before the first embryonic heart beat.

6 the complex electrical system that makes the heart beat.

7 approximately one third of the period of the heart beat.

8 red electrocardiogram (ECG) gating over many heart beats.

9 l pressure waveform despite multiple ectopic heart beats.

10 elax as an integrated functional unit as the heart beats.

11 We move our eyes more often than our heart beats.

12 single volume acquisition was achieved in 24 heart beats.

13 and was embryonic lethal within days of the heart beating.

14 Why does the heart beat?

15 0.54 baseline vs. 5.64 +/- 0.67 bursts (100 heart beats)(1) mmHg(1) at 120 min; P < 0.05).

16 0.29 baseline vs. 4.74 +/- 0.71 bursts (100 heart beats)(1) mmHg(1) at 120 min; P < 0.05).

17 striking consistency in the total number of heart beats accrued over a lifetime across a range of an

18 yocyte model to study its role during normal heart beat and during electromechanical pacing protocols

19 e main driving force of net IVC flow was the heart beat and not respiration.

20 rations of which may be related to premature heart beats and arrhythmias.

21 ted MSNA indices (%(Delta)bursts, bursts/100 heart beats and signal averaged MSNA), attenuated H(+) a

22 The heart beats approximately 100,000 times per day in human

23 Data collected over >100 ms/heart beat are also susceptible to bulk cardiac and resp

24 but the molecular underpinnings of the first heart beat are not known, nor whether function determine

25 sing the speed of XB recruitment so that the heart beats at a rate commensurate with f(min).

26 o the arterial pulse at the frequency of the heart beat became maximal.

27 The decline in heart-beating brainstem dead organ donors has necessitat

28 ience validating a novel, noninvasive, whole heart, beat-by-beat, 3-dimensional mapping technology wi

29 diastolic LV/RV function in the brain-dead, heart-beating cadaver, which may contribute to early pos

30 rent from recipients of livers procured from heart-beating cadaveric donors (P=0.74, log-rank test).

31 , cells were isolated from the livers of non-heart-beating cadaveric mice long after death and transp

32 eir differentiation into cardiomyocytes (the heart beating cells) and (iii) hiPSCs-derived cardiomyoc

33 Fluctuations of the human heart beat constitute a complex system that has been stu

34 ), von Willebrand factor (12%), next-morning heart beat cycle length (6%), next-morning heart rate va

35 characterized by a progressive heart-beat-to-heart-beat decrease in the lag of SND relative to the AP

36 gnals, as measured by, for example, tests of heart beat detection, perform better in laboratory studi

37 oved from 30 kg Yorkshire pigs in a model of heart-beating donation and either preserved in cold hist

38 ified to carry out the tasks involved in non-heart-beating donation, and may even potentially comprom

39 as older or sicker donors and so-called non-heart-beating donation, now referred to as donation afte

40 influence transplant outcome after deceased heart beating donor kidney transplant in the United King

41 Outcomes after deceased heart beating donor kidney transplantation are good, but

42 r novel Bristol and Region Allocation by Non-heart beating Donor Score (BRANDS).

43 articularly suited to retrieval from the non-heart beating donor.

44 P) performed ex-vivo in islets isolated from heart-beating donor (HBD) and non heart-beating donor (N

45 on of NHBD recipients compared to a group of heart-beating donor (HBD) recipients from a single insti

46 solution (MPS) improves the function of non-heart-beating donor (NHBD) canine kidneys.

47 be a successful experience of controlled non-heart-beating donor (NHBD) liver transplantation.

48 Non-heart-beating donor (NHBD) livers are an untapped source

49 to resuscitate and maintain viability of non-heart-beating donor (NHBD) livers that have undergone si

50 lated from heart-beating donor (HBD) and non heart-beating donor (NHBD) rats.

51 iorates warm ischemic lung injury in the non-heart-beating donor (NHBD), thereby improving function w

52 Uncontrolled non-heart-beating donor (UNHBD) transplantation offers a maj

53 After removing one kidney (heart-beating donor [HBD]), the dog was exsanguinated.

54 riovenous extracorporeal removal of CO2 in a heart-beating donor awaiting organ harvest.

55 ygenation will be highly significant for non-heart-beating donor cells.

56 d NEVKP is feasible and safe in good quality heart-beating donor kidney grafts.

57 othermic ex vivo kidney perfusion (NEVKP) in heart-beating donor kidney transplantation.

58 impact of this technology in preserving non-heart-beating donor livers.

59 n of kidneys not subjected to warm ischemia (heart-beating donor model), but there was no evidence th

60 ility, which will advance the utility of non-heart-beating donor organs for cell therapy or other app

61 We studied non-heart-beating donor rats for global gene expression with

62 r transplant unit, and compared with matched heart-beating donor transplants as a case control analys

63 The heart-beating donor- and DCD-NEVLP-groups showed signifi

64 A control heart-beating-donor (HBD) group was taken as the next co

65 Non-heart beating donors (NHBD) can provide an alternative s

66 Donation of kidneys from non-heart beating donors (NHBD) is increasingly being used t

67 long-waiting patients with kidneys from non-heart beating donors has reduced waiting times without c

68 One kidney from 40 non-heart beating donors was allocated to the highest BRANDS

69 ctive oxygenation during HMP of kidneys from heart beating donors.

70 llografts procured in standard fashion, from heart-beating donors

71 f delayed graft function (DGF) compared with heart-beating donors (42.4% vs. 23.3%, respectively).

72 ibility of using livers from controlled, non-heart-beating donors (CNHBD) with good immediate graft f

73 Grafts from heart-beating donors (HBD), and from donors with 30 minu

74 tors from the donors were suspected from non-heart-beating donors (n=1) and cardiac-arrest donors (n=

75 Wide recruitment of non-heart-beating donors (NHBD) could significantly increase

76 Hepatic allografts from non-heart-beating donors (NHBD) have been cited as a means t

77 Non-heart-beating donors (NHBD) offer a potential source of

78 Non-heart-beating donors (NHBD) offer a promising potential

79 ticularly the case for organs taken from non-heart-beating donors (NHBD), but there is still a lack o

80 but little used, is that of kidneys from non-heart-beating donors (NHBD).

81 oeficient (Kfc), in lungs retrieved from non-heart-beating donors (NHBDs) and reperfused with the add

82 Non-heart-beating donors (NHBDs) are generally not deemed su

83 r transplantation (LT) using grafts from non-heart-beating donors (NHBDs) has been shown to be a succ

84 Non-heart-beating donors (NHBDs) have the potential to reduc

85 Use of liver grafts from non-heart-beating donors (NHBDs) warrants consideration so t

86 lated interest in the use of organs from non-heart-beating donors (NHBDs).

87 in the use of extended donors, including non-heart-beating donors (NHBDs).

88 y were inferior to those of hepatocytes from heart-beating donors (P < 0.05).

89 imals, this was inferior to hepatocytes from heart-beating donors (P < 0.05).

90 5 years), obese (weight >or=200 lb), and non-heart-beating donors and donors with an elevated amylase

91 Liver grafts procured from heart-beating donors and preserved by SCS served as cont

92 ecember 1998, 150 kidneys were procured from heart-beating donors and preserved in our laboratory by

93 Organs from non-heart-beating donors are attractive for use in cell ther

94 These data provide evidence that non-heart-beating donors could be a suitable source of hepat

95 Similarly, although hepatocytes from non-heart-beating donors engrafted and proliferated after tr

96 Consent for cornea donation from non-heart-beating donors is often requested by means of tele

97 to molecular changes in hepatocytes from non-heart-beating donors offer opportunities for improving d

98 Pig LT was performed with livers from heart-beating donors or donation after circulatory death

99 Ethical controversies in the use of non-heart-beating donors remain despite thorough review.

100 n profiling in hepatocytes isolated from non-heart-beating donors showed far greater perturbations co

101 allocation scheme for kidneys from deceased heart-beating donors was required in the United Kingdom

102 , open-label, monocenter trial, 160 deceased heart-beating donors were allowed to perform 236 renal t

103 Grafts obtained from heart-beating donors were compared with donation after c

104 organ transplantations, split grafts, or non-heart-beating donors were not included.

105 hemia time, prolonged donor hypotension, non-heart-beating donors) who received thymoglobulin inducti

106 veral strategies, such as live donation, non-heart-beating donors, and expanded criteria donors.

107 ct over prolonged periods after death in non-heart-beating donors, but extensive molecular perturbati

108 ssfully isolated viable hepatocytes from non-heart-beating donors, especially up to 4 hours after dea

109 Use of non-heart-beating donors, international organ sharing, and p

110 In non-heart-beating donors, liver tissue was morphologically i

111 e hundred kidneys were locally procured from heart-beating donors, preserved in our laboratory, and t

112 nvolved in withdrawal of life support in non-heart-beating donors, unless specialty trained in end-of

113 donor organs including those from viable non-heart-beating donors.

114 Specimens were taken from 13 heart-beating donors.

115 urs after death, respectively, compared with heart-beating donors.

116 e similar to 242 synchronous recipients from heart-beating donors.

117 ntroversies remain concerning the use of non-heart-beating donors.

118 treated with water survived (i.e., palpable heart beat) for 16.0+/-0.5 days (n=6).

119 The relationship between heart beat frequency and the rate of oxygen consumption

120 At the 1st to the 3rd heart beat from the onset of stretch, MSNA (199 +/- 30%,

121 ntries, to measure whether the potential for heart-beating (HB) deceased donors was adequately conver

122 protein-labeled nerve terminals, to monitor heart beat in intact and semi-intact preparations.

123 issues, were able to successfully accelerate heart beating in vivo in rats.

124 and represents the temporary deceleration of heart beats in response to negative outcomes.

125 The null hypotheses were that heart beat interval fluctuations at usual breathing freq

126 The SERCA group shows longer heart beat intervals (Mean +/- SD: 1009.7 +/- 151.6 ms)

127 A synchronized heart beat is controlled by pacemaking impulses conducte

128 A rhythmic heart beat is coordinated by conduction of pacemaking im

129 The rhythmic heart beat is coordinated by electrical impulses transmi

130 The heart beat is coordinated by the integrated activities o

131 A regular heart beat is dependent on a specialized network of pace

132 atisfactorily assesses and preserves the non-heart-beating lung.

133 the oxygen pulse (ie, the O2 utilization per heart beat) mirrored that of peak VO2, whereas the longi

134 MT (-0.8 +/- 0.7 vs. 0.0 +/- 0.8 bursts/100 heart beats/mmHg, P = 0.052).

135 ing gap between organ supply and demand, non-heart-beating (NHB) donors will become increasingly impo

136 om 42.0 +/- 10.1 to 42.7 +/- 11.8 bursts/100 heart beats; NS).

137 Currently, there is no consensus on whether heart beat or respiration is the main driving force of v

138 y in the transplantation of kidneys from non-heart-beating or marginal donors or organs experiencing

139 Non-heart-beating organ donation for transplantation is incr

140 Further, non-heart-beating organ donation has failed to produce the w

141 In a small study of non-heart-beating organ donation, circulation never resumed

142 sthesiologists should not be involved in non-heart-beating organ donations; potential exceptions incl

143 All non-brain-dead patients who became non-heart-beating organ donors at the University of Pittsbur

144 tation and deaths of patients who became non-heart-beating organ donors.

145 g the arm and hand) was performed in 9 human heart-beating organ donors.

146 ic (CAD) organs and compare the results with heart-beating organ sources.

147 ts frequently become involved with such 'non-heart-beating' organ donations when they are asked to wi

148 after MT (-12 +/- 5 vs. -3 +/- 7 bursts/100 heart beats, P = 0.013).

149 om 53.3 +/- 12.2 to 47.4 +/- 11.5 bursts/100 heart beats; P < 0.01) but not in healthy subjects (from

150 tients receiving transplants from obese, non-heart-beating, pediatric, or hyperamylasemic donors comp

151 pumped from the ventricle and the number of heart beats per minute, a measure of the blood available

152 e analysis of the effects of respiration and heart beat provides new insights into the abnormal venou

153 ovascular defects, including an abnormal low heart beat rate (bradycardia) and severely hypoplastic S

154 Heart beat rate analysis and metabolome analysis indicat

155 oth the Phe-Met-Arg-Phe-amide maturation and heart beat rate defects observed in Ctr1A mutant larvae

156 In sinoatrial node cells of the heart, beating rate is controlled, in part, by local Ca(

157 Voluntary movement and the heart beat require this calcium flow to be massive and f

158 hase walk was characterized by a progressive heart-beat-to-heart-beat decrease in the lag of SND rela

159 ess of defibrillation, return of spontaneous heart beat, weanability from extracorporeal cardiopulmon